Literature DB >> 10612355

Basic mechanisms of gabitril (tiagabine) and future potential developments.

B S Meldrum1, A G Chapman.   

Abstract

Gabitril (tiagabine) is a potent selective inhibitor of the principal neuronal gamma-aminobutyric acid (GABA) transporter (GAT-1) in the cortex and hippocampus. By slowing the reuptake of synaptically-released GABA, it prolongs inhibitory postsynaptic potentials. In animal models of epilepsy, tiagabine is particularly effective against kindled (limbic) seizures and against reflexly-induced generalized convulsive seizures. These data are predictive of its efficacy in complex partial seizures in humans. Possible clinical applications outside the field of epilepsy include bipolar disorder and pain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10612355     DOI: 10.1111/j.1528-1157.1999.tb02087.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  11 in total

1.  Isobolographic Analysis of Antiseizure Activity of the GABA Type A Receptor-Modulating Synthetic Neurosteroids Brexanolone and Ganaxolone with Tiagabine and Midazolam.

Authors:  Shu-Hui Chuang; Doodipala Samba Reddy
Journal:  J Pharmacol Exp Ther       Date:  2019-12-16       Impact factor: 4.030

2.  Distinct gene expression profiles directed by the isoforms of the transcription factor neuron-restrictive silencer factor in human SK-N-AS neuroblastoma cells.

Authors:  Stuart G Gillies; Kate Haddley; Sylvia A Vasiliou; Gregory M Jacobson; Bengt von Mentzer; Vivien J Bubb; John P Quinn
Journal:  J Mol Neurosci       Date:  2010-07-23       Impact factor: 3.444

Review 3.  Mood disorders in patients with epilepsy: epidemiology and management.

Authors:  Cynthia L Harden; Martin A Goldstein
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

Review 4.  Emerging roles of Na⁺/H⁺ exchangers in epilepsy and developmental brain disorders.

Authors:  Hanshu Zhao; Karen E Carney; Lindsay Falgoust; Jullie W Pan; Dandan Sun; Zhongling Zhang
Journal:  Prog Neurobiol       Date:  2016-03-08       Impact factor: 11.685

5.  Dravet Syndrome: A Sodium Channel Interneuronopathy.

Authors:  William A Catterall
Journal:  Curr Opin Physiol       Date:  2017-12-23

6.  A controlled study comparing visual function in patients treated with vigabatrin and tiagabine.

Authors:  G L Krauss; M A Johnson; S Sheth; N R Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-03       Impact factor: 10.154

7.  Tiagabine does not attenuate alcohol-induced activation of the human reward system.

Authors:  Christoph Fehr; Nina Hohmann; Gerhard Gründer; Thomas F Dielentheis; Hans-Georg Buchholz; Natalie Chechko; Igor Yakushev; Christian Landvogt; Peter Bartenstein; Reinhard Urban; Mathias Schreckenberger
Journal:  Psychopharmacology (Berl)       Date:  2007-01-30       Impact factor: 4.530

Review 8.  Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse.

Authors:  C E Van Skike; S E Maggio; A R Reynolds; E M Casey; M T Bardo; L P Dwoskin; M A Prendergast; K Nixon
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2015-11-12       Impact factor: 5.067

9.  RNA-seq analysis and compound screening highlight multiple signalling pathways regulating secondary cell death after acute CNS injury in vivo.

Authors:  Chiara Herzog; David Greenald; Juan Larraz; Marcus Keatinge; Leah Herrgen
Journal:  Biol Open       Date:  2020-05-04       Impact factor: 2.422

10.  N-Substituted Nipecotic Acids as (S)-SNAP-5114 Analogues with Modified Lipophilic Domains.

Authors:  Michael C Böck; Georg Höfner; Klaus T Wanner
Journal:  ChemMedChem       Date:  2020-04-07       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.